Cardica Announces Fiscal 2013 Fourth Quarter And Full Year Financial Results PR Newswire REDWOOD CITY, Calif., Aug. 5, 2013 REDWOOD CITY, Calif., Aug. 5, 2013 /PRNewswire/ -- Cardica, Inc. (Nasdaq: CRDC) today announced financial results for its fiscal fourth quarter and full year ended June 30, 2013. Cardica's management will hold a conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide an update on the company's business. "In fiscal 2013 Cardica's main focus was to introduce the MicroCutter XCHANGE™ 30 for human use, while carefully monitoring performance and continuing to iterate the device in response to surgeons' feedback," said Bernard A. Hausen, M.D., Ph.D., president and CEO of Cardica. "In addition, we reinitiated a major clinical trial to support a 510(k) submission. Midway through the fiscal year, we began a controlled launch for the MicroCutter XCHANGE™ 30 in Europe, working with key surgeons to demonstrate the features and benefits of this device in a host of different surgical procedures." Dr. Hausen continued, "Now at the end of fiscal 2013, we are proud to have successfully completed the MicroCutter European Trial (MET1) with very encouraging results. We clearly met the primary endpoint of the trial, freedom of MicroCutter-related severe adverse events when compared to historical controls from the medical literature, with only one event in 160 patients enrolled and 423 deployments. From a broad perspective our goal is, and has always been, to have a product that clearly meets surgeons' expectations in terms of reliability, repeatability and ease of use while offering key benefits in terms of size and mobility. It is the combination of both that will ensure success of this product in the U.S., the world's key market for medical stapling products, pending marketing clearance by the U.S. Food and Drug Administration." Recent Highlights and Accomplishments: oCompleted our MicroCutter European Trial where we evaluated the MicroCutter XCHANGE 30. oThe primary endpoint of the trial has been met with only one MicroCutter-related event in 160 enrolled patients with 423 deployments; oThe secondary endpoint analysis, acute procedural success, demonstrated a learning curve in device reliability typical for novel technology. Any issues in the initial phase of enrollment were quickly addressed resulting in substantial reliability growth and good procedural success in the second half of the enrollment period. None of the device-related issues resulted in a severe adverse event or a change in surgical procedure. oCompleted more than 1,200 deployments in more than 420 procedures with the XCHANGE 30 device since May 2012; oThe XCHANGE 30 continues to be used in a variety of complex procedures in the European Union including intestinal, lung and liver resections, pediatric procedures for congenital diseases, and others; oShipped 73 MicroCutter XCHANGE™ 30 devices and 420 XCHANGE™ 30 cartridges in the fiscal fourth quarter; oIncreased cumulative worldwide shipments of PAS-Port^® Proximal Anastomosis Systems to over 32,600 units, with 1,049 units shipped in the fiscal 2013 fourth quarter; and, oIncreased cumulative worldwide shipments of C-Port^® Distal Anastomosis Systems to over 13,800 units, with 130 units shipped in the fiscal 2013 fourth quarter. Fiscal 2013 Fourth Quarter and Full Year Ended June 30, 2013 Financial Results Total product sales were approximately $0.8 million for both the fiscal 2013 and fiscal 2012 fourth quarters. License and development revenue was $84,000 for both the fiscal 2013 and fiscal 2012 fourth quarters, with license and development revenue from both periods a result of the August 2010 agreement with Intuitive Surgical. Total net revenue was approximately $0.9 million for each of the fiscal 2013 and fiscal 2012 fourth quarters. Cost of product sales was approximately $0.9 million for the fiscal 2013 fourth quarter compared to approximately $0.8 million for the same period of fiscal 2012. Research and development expenses were approximately $2.3 million for the fiscal 2013 fourth quarter compared to $2.2 million for the fiscal 2012 fourth quarter. Selling, general and administrative expenses were approximately $1.4 million for the fiscal 2013 fourth quarter compared to $1.5 million for the fiscal 2012 fourth quarter. The net loss for the fiscal 2013 fourth quarter was approximately $3.9 million, or $0.08 per share, compared with a net loss of approximately $3.6 million, or $0.10 per share, in the fiscal 2012 fourth quarter. Total net revenue was approximately $3.5 million for the year ended June 30, 2013, compared to approximately $3.7 million for the year ended June 30, 2012. Total operating costs and expenses for fiscal 2013 were approximately $19.2 million compared to approximately $17.0 million for fiscal 2012. Net loss for fiscal 2013 was approximately $16.1 million, or $0.40 per share, compared to approximately $13.6 million, or $0.44 per share for fiscal 2012. Cash and short term investments as of June 30, 2013, were approximately $12.4 million compared with $17.0 million at March 31, 2013. As of June 30, 2013, there were approximately 51 million shares of common stock outstanding. Conference Call Details To access the live conference call on August 5, 2013, at 4:30 p.m. Eastern Time via phone, please dial 866-515-2912 from the United States and Canada or 617-399-5126 internationally. The conference ID is 98195935. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately two hours after the call through August 12, 2013, and may be accessed by dialing 888-286-8010 from the United States and Canada or 617-801-6888 internationally. The replay passcode is 33703897. To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company's website at www.cardica.com. Please connect to the website at least 15 minutes prior to the presentation to allow for any necessary software downloads. The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents at www.streetevents.com, a password-protected event management site. AboutCardica Cardicadesigns and manufactures proprietary stapling and anastomotic devices for cardiac and laparoscopic surgical procedures.Cardica's technology portfolio is intended to minimize operating time and enable minimally-invasive and robot-assisted surgeries. Cardica manufactures and markets its automated anastomosis systems, the C-Port^® Distal Anastomosis Systems and PAS-Port^® Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery, and has shipped over 46,400 units throughout the world. In addition,Cardicais developing the Cardica^® MicroCutter XCHANGE™ 30, a cartridge-based microcutter device with a five-millimeter shaft diameter, and the Cardica^® MicroCutter XCHANGE™ 45, a cartridge-based microcutter device with an eight-millimeter shaft. Both MicroCutter devices are designed to be used in a variety of procedures, including bariatric, colorectal, thoracic and general surgery. The Cardica MicroCutter XCHANGE 30 and XCHANGE 45 products require 510(k) review and are not yet commercially available in the U.S. Forward-Looking Statements The statements in this press release regarding Cardica's belief that the MicroCutter product will be successful in the US, pending marketing clearance by the U.S. Food and Drug Administration is a "forward-looking statement." The words "expect" and "anticipated" are intended to identify these forward-looking statements. There are a number of important factors that could cause Cardica's results to differ materially from those indicated by these forward-looking statements, including: that Cardica may not be successful in its efforts to further develop or commercialize the XCHANGE 30 due to unanticipated technical or other difficulties; that the XCHANGE 30 may face unanticipated development, regulatory, or manufacturing delays; that review by FDA could alter the results as presented herein; that Cardica's intellectual property rights may not provide adequate protection to enable further development of the XCHANGE 30; that surgeons may not use the XCHANGE 30 correctly, which could cause unfavorable results that may impair the acceptance of the XCHANGE 30 by other surgeons; and that Cardica may not have sufficient funds to develop the XCHANGE 30, as well as other risks detailed from time to time in Cardica's reports filed with the U.S. Securities and Exchange Commission, including its Current Report on Form 10-Q for the quarter endedMarch 31, 2013, under the caption "Risk Factors." Cardica expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Cardica's reports filed with the U.S. Securities and Exchange Commission, available at www.sec.gov. Cardica, Inc. Statements of Operations (amounts in thousands except per share amounts) Three months ended Twelve months ended June 30, June 30, 2013 2012 2013 2012 (unaudited) (unaudited) Revenue Product sales, net $ $ $ 3,093 $ 3,274 771 844 License and development revenue 84 84 336 336 Royalty revenue 17 18 70 71 Total 872 946 3,499 3,681 Operating costs and expenses Cost of product sales 915 763 3,604 3,638 Research and development 2,297 2,221 9,145 7,220 Selling, general and 1,370 1,471 6,410 6,139 administrative Total operating costs 4,582 4,455 19,159 16,997 and expenses Loss from operations (3,710) (3,509) (15,660) (13,316) Interest and other income (loss), (31) 4 (20) 9 net Interest expense (118) (107) (457) (268) Net loss $ $ $ $ (3,859) (3,612) (16,137) (13,575) Basic and diluted net loss per $ $ $ $ share (0.08) (0.10) (0.40) (0.44) Shares used in computing basic 51,060 36,408 40,842 30,547 and diluted net loss per share Balance Sheets (amounts in thousands) June 30, June 30, 2013 2012 Assets (unaudited) Cash and cash equivalents $ 12,395 $ 14,645 Accounts receivable 391 299 Inventories 1,457 576 Other assets 3,518 2,622 Total assets $ 17,761 $ 18,142 Liabilities and stockholders' equity Accounts payable and other liabilities $ 1,945 $ 1,860 Deferred revenue 2,054 2,390 Long term debt 2,788 2,532 Total stockholders' equity 10,974 11,360 Total liabilities and stockholders' $ 17,761 $ 18,142 equity SOURCE Cardica, Inc. Website: http://www.cardica.com Contact: Bob Newell, Vice President, Finance and Chief Financial Officer, (650) 331-7133, email@example.com
Cardica Announces Fiscal 2013 Fourth Quarter And Full Year Financial Results
Press spacebar to pause and continue. Press esc to stop.